Recombinant Human LCAT Protein (C-6His)

Beta LifeScience SKU/CAT #: BL-0707NP
BL-0707NP: Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
BL-0707NP: Greater than 95% as determined by reducing SDS-PAGE. (QC verified)

Recombinant Human LCAT Protein (C-6His)

Beta LifeScience SKU/CAT #: BL-0707NP
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description Recombinant Human Lecithin-cholesterol Acyltransferase is produced by our Mammalian expression system and the target gene encoding Phe25-Glu440 is expressed with a 6His tag at the C-terminus.
Accession P04180
Synonym Phosphatidylcholine-sterol acyltransferase; also named Lecithin-cholesterol acyltransferase; Phospholipid-cholesterol acyltransferase and LACT; is an extracellular cholesterol esterifying enzyme which belongs to the AB hydrolase superfamily.
Gene Background Lipase family. The gene encoding this protein is expressed mainly in brain, liver and testes,followed by secreting into plasma and cerebral spinal fluid. The esterification of cholesterol is required for cholesterol transport. LCAT is a central enzyme in the extracellular metabolism of plasma lipoproteins. Defects in LCAT are the cause of lecithin-cholesterol acyltransferase deficiency (LCATD) and a cause of fish-eye disease (FED).
Molecular Mass 48.1 KDa
Apmol Mass 66 KDa, reducing conditions
Formulation Lyophilized from a 0.2 μm filtered solution of 4mM HCl.
Endotoxin Less than 0.1 ng/µg (1 EU/µg) as determined by LAL test.
Purity Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
Biological Activity Not tested
Reconstitution Always centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
Storage Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below.
Usage For Research Use Only

Target Details

Target Function Central enzyme in the extracellular metabolism of plasma lipoproteins. Synthesized mainly in the liver and secreted into plasma where it converts cholesterol and phosphatidylcholines (lecithins) to cholesteryl esters and lysophosphatidylcholines on the surface of high and low density lipoproteins (HDLs and LDLs). The cholesterol ester is then transported back to the liver. Has a preference for plasma 16:0-18:2 or 18:O-18:2 phosphatidylcholines. Also produced in the brain by primary astrocytes, and esterifies free cholesterol on nascent APOE-containing lipoproteins secreted from glia and influences cerebral spinal fluid (CSF) APOE- and APOA1 levels. Together with APOE and the cholesterol transporter ABCA1, plays a key role in the maturation of glial-derived, nascent lipoproteins. Required for remodeling high-density lipoprotein particles into their spherical forms. Catalyzes the hydrolysis of 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor or PAF) to 1-O-alkyl-sn-glycero-3-phosphocholine (lyso-PAF). Also catalyzes the transfer of the acetate group from PAF to 1-hexadecanoyl-sn-glycero-3-phosphocholine forming lyso-PAF. Catalyzes the esterification of (24S)-hydroxycholesterol (24(S)OH-C), also known as cerebrosterol to produce 24(S)OH-C monoesters.
Subcellular Location Secreted.
Protein Families AB hydrolase superfamily, Lipase family
Database References

HGNC: 6522

OMIM: 136120

KEGG: hsa:3931

STRING: 9606.ENSP00000264005

UniGene: PMID: 30055622

  • Single Nucleotide Polymorphism in LCAT gene is associated with dyslipidemia. PMID: 29758034
  • data suggests a model wherein the active site of LCAT is shielded from soluble substrates by a dynamic lid until it interacts with HDL to allow transesterification to proceed PMID: 29030428
  • Increased LCAT activity may be associated with increased formation of triglyceride rich lipoproteins, leading to a reduction in LDL particle size and atherosclerosis. PMID: 25894629
  • Mapping the naturally occurring mutations onto the structure provides insight into how they may affect LCAT enzymatic activity. PMID: 26195816
  • Report slightly reduction in LCAT that would probably reflect a delay in reverse cholesterol transport occurring in MetS. PMID: 26232163
  • rs5923 polymorphism is not associated with low high-density lipoprotein cholesterol(HDL-C)levels in Iranian population PMID: 26117245
  • increased cholesterol esterification by LCAT is atheroprotective PMID: 25964513
  • The data indicate that this novel apoA-I missense is associated with markedly decreased levels of HDL cholesterol and very large alpha-1 HDL, as well as decreased serum cellular cholesterol efflux and LCAT activity PMID: 26073399
  • A robust all-atom model for LCAT generated by homology modeling PMID: 25589508
  • genetic polymorphism is associated with coronary artery disease in Egyptians PMID: 25110219
  • This study investigated how the natural LCAT[T147I] and LCAT[P274S] mutations affect the pathway of biogenesis of high-density lipoproteins. PMID: 25948084
  • A synonymous H287H mutation in the coding region of exon 6 of the lecithin cholesterol acyltransferase gene was observed in an individual with HDLC levels of 75 mg/dl. PMID: 24789697
  • Cosyntropin testing in an unselected subgroup of 8 ABCA1 mutation carriers and 3 LCAT mutation carriers did not reveal differences between carriers and controls. PMID: 24842300
  • The enzyme lecithin-cholesterol acyltransferase esterifies cerebrosterol and limits its toxic effect on cultured neurons. PMID: 24620755
  • Activity of LCAT in HDL was increased in type 2 diabetes following increased fruit and vegetable intake. PMID: 24423117
  • Results show that recombinant lecithin:cholesterol acyltransferase rhLCAt efficiently reduces the amount of unesterified cholesterol and promotes the production of plasma cholesteryl esters in LCAT deficient plasma. PMID: 24140107
  • The present study provides an important insight into the potential interactions between LCAT and lipoproteins and also suggests that peptides, initially present in a disordered conformation, are able to sense the lipid environment provided by lipoproteins of plasma and following a disorder-to-order transition, change their conformation to an ordered alpha-helix. PMID: 24383078
  • Male soccer players had significantly higher lecithin-cholesterol acyltransferase activity than sedentary controls. PMID: 23152129
  • a novel function of apoA-IV in the biogenesis of discrete HDL-A-IV particles with the participation of ABCA1 and LCAT PMID: 23132909
  • Pulse wave velocity is increased in LCAT mutation carriers with low HDL-c and is associated with carotid wall thickening. PMID: 23078883
  • carriers of LCAT mutations present with significant reductions in LCAT activity, HDL cholesterol, apoA-I, platelet-activating factor-acetylhydrolase activity and antioxidative potential of HDL, but this is not associated with parameters of increased lipid peroxidation PMID: 23023370
  • while LCAT activity is decreased in patients with T2DM, LCAT levels is increased. Patients with NIDDM exhibit opposing effects on LCAT activity and LCAT production which is more severe in women PMID: 23142243
  • Studies suggest that absence of lecithin cholesterol acyltransferase (LCAT) may protect against insulin resistance, diabetes and obesity. PMID: 22326749
  • mutations in ABCA1, APOA1, and LCAT are sufficient to explain more tha 40 percent of familial hypoalphalipoproteinemia PMID: 21875686
  • This review focuses on mutations in the LCAT gene as cause of familial hypoalphalipoproteinemia, and on their impact on plasma HDL-C, HDL profile and coronary heart disease. PMID: 22189200
  • Studies indicate the direct effects of HDL and its major modulators, ATP-binding cassette transporter A1 (ABCA1), apolipoprotein A-I (ApoA-I), and lecithin cholesterol acyltransferase (LCAT) on the development of type 2 diabetes mellitus (T2D). PMID: 22418575
  • functional mutations in LCAT were found in 29% of patients with low HDL-c, thus constituting a common cause of low HDL-c in referred patients in The Netherlands (LCAT) PMID: 21901787
  • Low plasma HDL cholesterol levels robustly associated with increased risk of MI but genetically decreased HDL cholesterol did not. PMID: 22090275
  • Continuous and intermittent walking alters HDL(2)-C and LCATa PMID: 21798542
  • AAV8-mediated overexpression of human LCAT in hCETP/Ldlr(+/-) mice resulted in profound changes in plasma lipid profiles. PMID: 21822774
  • Carriers of LCAT gene mutations exhibit increased carotid atherosclerosis PMID: 22133847
  • analysis of a mutation that causes a complete loss of catalytic activity of LCAT, which is also defective in secretion [case report] PMID: 21597230
  • LCAT activity and enzyme levels were significantly lower among subjects with low HDL-C compared with subjects with high HDL-C. PMID: 21600519
  • Case Report: familial LCAT deficienty can cause nephropathy at a very early age. PMID: 21315357
  • Novel N-terminal mutation of human apolipoprotein A-I reduces self-association and impairs LCAT activation PMID: 20884842
  • LCAT activity is significantly decreased in type 2 diabetes. The lower LCAT activity in type 2 diabetes might be through ox-LDL mechanism. Ox-LDL may adversely affect high-density lipoprotein -cholesterol metabolism by reducing LCAT activity. PMID: 20890173
  • Plasma lecithin: cholesterol acyltransferase activity modifies the inverse relationship of C-reactive protein with HDL cholesterol in nondiabetic men. PMID: 19800416
  • lecithin:cholesterol acyltransferase activity is not responsible for low incidence of cardiovascular events PMID: 19698944
  • Low LCAT plasma levels are not associated with increased atherosclerosis in the general population. PMID: 19671930
  • Suggest that a LCAT-/- genotype associated with an APOE epsilon2 allele could be a novel mechanism leading to dysbetalipoproteinemia in familial LCAT deficient patients. PMID: 19515369
  • The lecithin:cholesterol acyltransferase (LCAT) activity in cord blood was extremely low. PMID: 11882335
  • Results suggest that LCAT may take part in the detoxification of oxidants even after the loss of its cholesterol esterification function. PMID: 11966470
  • IL-6 induced activation of full-length LCAT promoter activity. A minimal IL-6 response element mapped within the distal promoter and was sufficient to mediate the IL-6 response PMID: 12032172
  • In conclusion, 12% of Hypoalphalipoproteinemia subjects were found to carry mutations in apo A-I, LCAT, or GBA genes PMID: 12048121
  • The results suggest that as follicle maturation progresses, Toc and Asc concentrations increase in follicular fluid, thus protecting LCAT from oxidative damage and loss of activity PMID: 12051518
  • Endotoxin-lipoprotein complex formation as a factor in atherogenesis: associations with hyperlipidemia and with lecithin:cholesterol acyltransferase activity PMID: 12139471
  • comparison of 5 natural point mutations of apo A-I illustrates that a specific sequence between amino acids 110 and 162 is required for LCAT activation PMID: 12573451
  • 608T polymorphism of LCAT gene was associated with higher plasma HDL-C level in Coronary Arteriosclerosis patients. PMID: 12673583
  • Familial lecithin:cholesterol acyltransferase (LCAT) deficiency, arising from mutation, is associated with complete absence of Lecithin:cholesterol acyltransferase (LCAT) activity. PMID: 12957688
  • FAQs

    Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

    Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

    Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

    Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

    Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

    Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

    To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

    Recently viewed